Did ravulizumab improve the patients’ quality of life?
Two questionnaires were used in the study to measure how patients rated their quality of life.
One questionnaire focused on tiredness, and the other questionnaire focused on overall health.
The researchers compared the answers to the questionnaires at the start of the study and after
26 weeks of treatment with ravulizumab.
TIREDNESS OVERALL HEALTH
The majority of patients reported The majority of patients reported an
feeling less tired during 26 weeks improvement in their overall health during
of treatment with ravulizumab. 26 weeks of treatment with ravulizumab.
How many patients responded to ravulizumab during 52 weeks
of treatment?
The researchers compared the patients’ blood parameters from the start of the study to the end of
52 weeks of treatment. Blood parameters returned to a normal range for most of the patients.
During 52 weeks of treatment, 34 out of 56 patients (61%) had a complete
61%
response to ravulizumab.
LDH LEVELS PLATELET COUNT CREATININE LEVELS
84% 86% 63%
LDH levels for The platelet count for Creatinine levels for
47 out of 56 patients (84%) 48 out of 56 patients (86%) 35 out of 56 patients (63%)
decreased to a normal range. increased to a normal range. decreased by at least 25%.
Protocol, ALXN1210-aHUS-311 SPONSOR CONTACT INFORMATION:
Europe, 2016-002027-29 1-888-765-4747
© Certara USA, Inc. 2020. All rights reserved United States, NCT02949128 medinfo@alexion.com 8